Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 55,100 shares, a growth of 9.8% from the December 15th total of 50,200 shares. Currently, 10.3% of the shares of the company are short sold. Based on an average daily volume of 224,100 shares, the days-to-cover ratio is presently 0.2 days.

Bone Biologics Price Performance

Shares of BBLG stock opened at $0.98 on Monday. The stock has a 50 day simple moving average of $1.11 and a 200-day simple moving average of $1.43. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $4.74.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.